NAPA, Calif., Nov. 10 /PRNewswire/ -- Integrated Biosystems, Inc. (IBI), the world's leading supplier of controlled freeze-thaw technology to the biopharmaceutical industry, today announced that two new patents have issued in October bringing the total company patent portfolio to nine issued patents. In addition, nine patent applications are pending.
U.S. Patent No. 6,631,616 (the " '616 Patent") issued on October 14 and U.S. Patent No. 6,635,414 (the " '414 Patent") issued on October 21. Both are entitled "Cryopreservation system with controlled dendritic freezing front velocity" and are related to IBI's new Celsius product line, which provides controlled freeze-thaw technology in disposable containers.
The '616 patent, authored by Richard Wisniewski, Chief Technology Officer and Eric K. Lee, Vice President of Research and Development for Integrated Biosystems, Inc., relates to freezing of a biopharmaceutical material in a container through the contact of one or more heat transfer surfaces. The '414 patent, meanwhile, relates to a system that enables the controlled freezing of biopharmaceuticals in flexible sterile containers. The patents add further protection to the unique principles of IBI's freeze-thaw technology that may help overcome problems such as cryoconcentration and/or lack of scalability associated with conventional methods.
"The issuance of these patents recognizes the fundamental strength of Integrated Biosystems' technology," commented Dr. Eric Lee. "It supports the company's continued growth as the market leader in controlled freezing and thawing of biopharmaceutical materials."
By extending the technology for use with flexible containers -- which IBI will market under the brand name Celsius-Pak -- the company now has access to a larger market. Many biopharmaceutical manufacturers have seen the advantages of using disposable products, such as the elimination of expensive cleaning procedures and are keen to incorporate them into their manufacturing processes. The new Celsius product line offers this possibility and has already been reviewed and well received by several large Biopharma companies. The first product will be shipped before the end of this year with full launch of the new product line starting in 2004.
Asked about the importance of these patents, John H. Brown, President and Chief Executive Officer of Integrated Biosystems said, "An essential component of building a successful company in this industry is the ability to develop a strong intellectual property portfolio. With the issuance of these two patents IBI continues to demonstrate the value that its technology brings to the biopharmaceutical manufacturing market."
About Integrated Biosystems, Inc.
Integrated Biosystems, Inc. (IBI) is the world's leading supplier of patented technology and equipment for the controlled freezing, thawing and frozen storage of biopharmaceutical intermediates and final bulk drug substances. IBI's product portfolio includes freeze-thaw systems and related handling equipment for R&D, Pilot and Full-Scale Manufacturing. The technology has been used for over 10 years at leading Biotech and Biopharma contract manufacturers and is currently an integral part of the manufacture of a variety of leading biopharmaceuticals.
IBI is a private company headquartered in Napa, CA with European facilities in Fribourg (Switzerland) and Aubagne (France) and Engineering and Manufacturing operations in Springfield, MO.
For further information contact Richard Eagling, Vice-President Marketing and General Manager, Europe (firstname.lastname@example.org) or go to http://www.integratedbio.com/
Integrated Biosystems, Inc.